FDA approves drug for postmenopausal symptoms

Article

The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

 

The first drug combining estrogens with bazedoxifene has been approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

Produced by Wyeth Pharmaceuticals, Duavee is indicated only for postmenopausal women who still have their uterus. Bazodoxifene reduces the risk of endometrial hyperplasia.

The FDA advises that clinicians prescribe Duavee for the shortest period of time that will meet treatment needs. It can be given solely to prevent osteoporosis, but the indication is only for women at serious risk of losing bone mass and strength and after careful consideration of other non-estrogen drugs.

Common adverse effects observed during clinical trials with estrogen plus bazedoxifene included muscle spasm, nausea, diarrhea, dyspepsia, upper abdominal pain, oropharyngeal pain, dizziness, and neck pain. The drug will carry the same boxed warnings as other approved estrogen drugs.

 

 

To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.

Related Videos
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit: nursebarb.com
How fezolinetant changes management of hot flashes | Image Credit: medschool.cuanschutz.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.